BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity Of Bria-OTS+ And Bria-PROS+ Clinical Candidates For Breast And Prostate Cancer
- Preclinical data shows that BriaCell's Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic cells, and natural killer (NK) cells
- The novel mechanisms of action may lead to strong anti-cancer activity in breast and prostate cancer patients
PHILADELPHIA and VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today is pleased to report preclinical data showing strong anti-cancer activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies, Bria-OTS+™ and Bria-PROS+™, in a poster session during the 2024 American Association for Cancer Research (AACR) Annual Meeting held from April 5-10 at San Diego Convention Center, San Diego, CA.
"Our data demonstrates enhancement of immune responses and expanded mechanisms of action of the Bria-OTS+™ platform," commented Miguel A. Lopez-Lago, PhD, BriaCell's Chief Scientific Officer. "We anticipate that our novel immunotherapeutic platform will provide potent and long-lasting anti-cancer activity in cancer patients. We view our technology as a significant scientific advancement in the field of oncology and personalized immunotherapy."
"We are truly thrilled with our data confirming the robust immune system activation elicited by our novel next generation Bria-OTS+™ platform – featuring proprietary immune activating factors for improved efficacy," commented Dr. William V. Williams, BriaCell's President and CEO. "We have successfully enhanced antigen presentation activity and cytokine expression while expanding our HLA target range to cover nearly 99% of the population. We are looking forward to advancing our next generation Bria-OTS+™ and Bria-PROS+™ programs into the clinic."
The poster is summarized below and linked here: https://briacell.com/scientific-publications/.
Title: Bria-OTS+™ immunotherapy platform: Harnessing gene-modified tumor cells to reinvigorate the cancer immunity cycle for precision anti-tumor responses
Abstract Presentation Number: 6753
BriaCell has designed Bria-OTS+™, an immunotherapy platform representing the next generation (enhanced version) of Bria-OTS™, BriaCell's personalized off-the-shelf (i.e. pre-manufactured and ready for use) immunotherapy for cancer. Bria-OTS+™ immunotherapy expresses multiple immune activating cytokines and co-stimulatory molecules in addition to immune boosting granulocyte-macrophage colony-stimulating factor (GM-CSF). BriaCell expects to use Bria-OTS+™ and Bria-PROS+™ in its upcoming phase 1/2a clinical studies for breast and prostate cancer, respectively. Bria-PROS+™ has already entered GMP manufacturing to generate clinical supplies for the phase 1/2a study. The characteristics of the next generation Bria-OTS+™ immunotherapy platform include the following:
- Bria-OTS+™ and Bria-PROS+™ activate key components of the innate immune system which serves as the body's first line of defense against cancer
- Bria-OTS+™ and Bria-PROS+™ engage multiple facets of the adaptive immune response. This may result in lasting anti-cancer effects in patients
- Specifically activates Natural Killer (NK) cells to counter cancer immune escape caused by the loss of human leukocyte antigens (HLA)
- Designed for personalized and ready-to-use therapy with long term stability
- Simplified administration process of intradermal inoculations (injection into the skin) allows administration in a physician's office
- Anticipated to have a favorable side effect profile, indicating good tolerance (based on prior findings with Bria-IMT™)
Given ease of administration, potent, multi-faceted immune system activation, and favorable safety profile, BriaCell expects Bria-OTS+™ and Bria-PROS+™ to deliver significant clinical efficacy and survival benefits in breast cancer and prostate cancer, respectively.